Melanocortin (MC4R) agonistTier 1
BremelanotideA cyclic heptapeptide melanocortin (MC4R) agonist that acts centrally on sexual desire circuitry, FDA approved as Vyleesi for premenopausal HSDD.
MC4RReceptorFDA approvedStatus (Vyleesi)
View researchFnx Performance products are intended strictly for qualified in vitro laboratory research. For Research Use Only. Not for human or animal consumption. Not for compounding or therapeutic application.
Explore mechanism data, evidence tiers, safety, and regulatory context for every compound in the Fnx catalog. Each peptide has its own research profile, filter by category or follow a tag from any product page.
FDA approved with randomized controlled trials behind the approved use.
A large or maturing human RCT base, but not (yet) FDA approved for this use.
Registered and used abroad (e.g. Russia) on modest, mostly single institution trials.
A plausible mechanism, but human efficacy for the marketed use is unproven.
Animal/in vitro data and anecdote only, little to no human evidence and real safety unknowns.
A cyclic heptapeptide melanocortin (MC4R) agonist that acts centrally on sexual desire circuitry, FDA approved as Vyleesi for premenopausal HSDD.